Case Report of Dinutuximab-induced Atypical Hemolytic Uremic Syndrome
Letha Huang1, Danielle Miller1, Fouad Hajjar2
1Department of Pediatric Pharmacy Advent Health for Children.
Abstract:
Limited evidence exists describing the relationship between the development of atypical hemolytic uremic syndrome (aHUS) and the administration of dinutuximab. This case report describes a 20-year-old male with neuroblastoma who experienced aHUS post-dinutuximab administration. The patient presented with uncontrolled hypertension and renal dysfunction, ultimately receiving a definitive diagnosis of aHUS through a renal biopsy. The patient required complement-directed therapy with eculizmab and later transitioned to ravulizumab. This case further describes a sequential relationship between dinutuximab administration and aHUS development.
More Related Videos
07:39Renal Subcapsular Transplantation of 2'-Deoxyguanosine-Treated Murine Embryonic Thymus in Nude Mice
Published on: July 19, 2019
06:08Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model
Published on: February 10, 2023
Related Concept Videos
Drug Toxicity: Allergic Reactions
Hypersensitivity Reactions: Cytolytic Reactions
Nephrotic Syndrome I : Introduction
Nephrotic Syndrome II : Assessment and Medical Management
Acute Kidney Injury IV: Diagnostic Studies and Prevention
Chronic Kidney Disease II: Clinical Manifestations
